Your inquiries
Catalog of medicines India

Abevmy 400mg (Bevacizumab 400mg)

Abevmy 400mg (Bevacizumab 400mg)

Abevmy 400mg is indicated for the treatment of some of the conditions like :
Metastatic colon or rectal cancer
Non-squamous, non-small cell lung cancer
Metastatic renal cell cancer
Metastatic cervical cancer
Epithelial ovarian, fallopian tube or peritoneal cancer.

Brand name:
Active substance:
Bevacizumab 400mg
1 Vial
Product form:
In stock
Active substance: Bevacizumab 400mg
575 $
To wishlist


Bevacizumab is a drug sold under the name of Abevmy 400mg and which is categorized as monoclonal anti-body & anti-angiogenesis When Abevmy 400mg concomitant use with human monoclonal antibody IgG1, that circumstance and prohibits the biological action of human vascular endothelial growth factor (VEGF).


Abevmy 400mg is indicated for the treatment of some of the conditions like :

Metastatic colon or rectal cancer
Non-squamous, non-small cell lung cancer
Metastatic renal cell cancer
Metastatic cervical cancer
Epithelial ovarian, fallopian tube or peritoneal cancer.


Abevmy comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells
This interaction prevents endothelial cell multiplication and new blood vessel production occurs
Hence in counts cessation of metastatic cancer cells development happens



The volume of distribution is 2.9 (22%) L


The Bevacizumab half-life period is 20days (11 to 50days)


Key point:
Avoid administration of Abevmy before at least 28 days following surgery and the wound is completely cured
colorectal carcinoma:
Concomitant use with 5-fluorouracil based chemotherapy is the usual dosage of Abevmy: While concomitant use with bolus IFL the dose is 5mg/kg of Abevmy for every 2 weeks IV.
While in combination with FOLFOX4 the dose is 10mg/kg of Abevmy for every 2 weeks IV
5mg/kg IV Abevmy for every 2 weeks or 7.5 mg/kg Abevmy as IV every 3 weeks by concurrently used with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy
Non-small cell lung cancer:
While combining with carboplatin and paclitaxel: The Abevmy usual dosage is 15mg/kg IV for every 3 weeks by
For every 2 weeks: 10mg/kg of Abevmy administered IV
Metastatic renal cell cancer:
Concurrent use with interferon alfa: The Abevmy usual dosage is 10mg/kg IV for every 2 weeks
Metastatic cervical cancer:
Combining with paclitaxel and cisplatin or with paclitaxel and topotecan: The drug Abevmy usual dosage is 15mg/kg of Abevmy given intravenously for every 3 weeks
Epithelial ovarian, fallopian tube or peritoneal cancer:
Platinum opposing:
Concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan: The Abevmy regular dosage is 10mg/kg of Abevmy for every 2 weeks
Or Combining with topotecan: The Abevmy regular dosage 15mg/kg of Abevmy given through IV for every 3 weeks
Platinum responsive:
concomitant with carboplatin and paclitaxel for 6 to 8 cycles: The drug Abevmy recommended dosage of is 15mg/kg given IV for 3 weeks
Combining with gemcitabine & carboplatin for 6 to 10 cycles: The Abevmy recommended dosage is 15mg/kg of Abevmy given IV for 3 weeks
Preparation & administration:
Abevmy is intravenous solution
At initial infusion:
given IV infusion over 90 minutes
Following infusions:
give second infusion over 60 minutes, if tolerated
Administer all following infusion over 30minutes
Abevmy IV infusion is prepared in aseptic condition
Abevmy 400mg containing 16ml solution whereas 100mg containing 4ml
Abevmy dilute into 100ml of 0.9% NS
Do not dilute with dextrose solution
Dispose the remaining portion of medicine which is left in a vial.


Caution with use in the conditions like;
There are some complications occurred during treatment with Abevmy 400mg, care should be taken
Arterial thromboembolic events:
cessation of treatment with Abevmy 400mg in patients who are suffered with severe ATE.
Venous thromboembolic events:
Toxicity Incidence should be detected; If severe condition therapy should be stopped.
While on Abevmy 400mg treatment some Serious hemorrhages will occur like GI hemorrhage, hemoptysis, Hematemesis, CNS hemorrhage, nose bleeding & vaginal bleeding. Hence Discontinue the treatment.
Bp is increased in patients who are receiving Abevmy 400mg therapy, must be frequently check up with blood pressure and provided with alternative medication for correct the pressure.
In hypertension crisis or encephalopathy should be discontinue the treatment.
Posterior reversible encephalopathy syndrome
Embryo fetal toxicity occurs:
During pregnancy condition Abevmy 400mg is contraindicated which produce fetal harm.
Ovarian failure:
The patients who are receiving Abevmy 400mg may have a chance of getting ovarian failure.
Congestive heart failure:
the drug combination with anthracycline based chemotherapy, treatment with Abevmy 400mg must not be used. Abevmy 400mg treatment should be stopped while CHF occurs.


  • Gastrointestinal perforation and fistulae
    • Surgery and wound healing complication
    • Hemorrhage
    • Arterial thromboembolic events
    • Venous thromboembolic events
    • Hypertension
    • Posterior reversible encephalopathy syndrome
    • Renal injury & Proteinuria
    • Infusion reactions
    • Ovarian failure
    • Congestive heart failure
    • Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysesthesia.


Pregnancy category: D
While administrating Abevmy 400mg in pregnant women, positive evidence on fetal risk depends on human studies but potential benefits by using the drug may have common risk against fetus.


Abevmy 400mg is excreted into breast milk taking account on this, discussion should do on whether to discontinue the breast feeding or the drug. The drug is risky during mother breast feeding to their infants.


The drug stored at 2 to 8°C(36 to 46°F).
Single use vial
Dispose the left-out vial under the guidance of pharmacists.


The dose missed by patient should have the dose immediately before the next dose timing reaches or leave the missed dose and continue the regular schedule.
Remember do not have double dose at a time
Please consult with doctor for further details.



Brand name
Active substance
Bevacizumab 400mg
1 Vial
Product form
Abevmy 400mg (Bevacizumab 400mg)
Add a comment

There are no comments yet

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments.